Norgine Deal History & Licensing Activity
Norgine is a life sciences. Over the past three years, Norgine has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 4 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
4
Top Modality
Small Molecules
Focus Area
Rare Disease
Norgine Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Norgine in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| mavorixafor (XOLREMDI) | X4 Pharmaceuticals | Small Molecules | Phase 3 | license | Feb 2026 |
Norgine Pipeline Focus
Therapeutic areas and modalities where Norgine is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Norgine Strategic Signals
Key indicators of Norgine's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Norgine Clinical Pipeline
Norgine has 4 active clinical trials across 3 development phases.
1
Not Applicable
2
Phase 4
1
Phase 3
See How Your Asset Matches Norgine's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Norgine Licensing & Deal Activity
Norgine is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Norgine ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Norgine include Rare Disease (2 deals and trials), and Cardiovascular (1 deal and trial). In terms of modality, Norgine has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Norgine and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Norgine's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.